↑ Rising
Business
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
6sources
6articles
4velocity
+31%since first seen
1h agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (6)
- Sangamo Therapeutics files for bankruptcy as Lilly and Astellas split assets The Business Journals · 7h ago
- Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection citybiz · 7h ago
- Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans Law360 · 7h ago
- Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas TradingView · 7h ago
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy BioSpace · 7h ago
- Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers Fierce Biotech · 7h ago
Related trends
▲ Peaking
Business
N.S.A. Lost Access to Powerful A.I. Model Amid Anthropic Dispute
▲ Peaking
Business
Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program
▲ Peaking
Business
White-collar baby boomers are facing a dilemma: Embrace AI or retire early
▲ Peaking
Business
Anthropic’s Claude Tag is learning your company, one Slack message at a time
Anthropic's Claude Tag is now learning from Slack messages to function as a virtual employee
▲ Peaking
Business
Cerebras reports 92% revenue growth in chipmaker's first earnings report since IPO
Cerebras' first earnings report since its IPO shows significant revenue growth, drawing attention from major financial outlets.
▲ Peaking
Business